

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Attorney Docket No. 2006_0750A
Etsuko MIYAMOTO et al. : **Confirmation No. 9419**
Serial No. 10/579,802 : Group Art Unit 1636
Filed May 18, 2006 : Examiner Michele K. Joike
PROTEIN FORMING COMPLEX WITH : **Mail Stop: ISSUE FEE**
c-Jun PROTEIN, NUCLEIC ACID
ENCODING THE SAME AND METHOD OF
USING THE SAME

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached Form PTO/SB/08 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO/SB/08 is enclosed, except a copy is not provided for:

☒ each U.S. Patent and U.S. Patent application publication;

☐ each reference previously cited in prior parent application
Serial No. _____.

1a. ☐ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

The USPTO is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.492, which may be required by this paper to Deposit Account No. 23-0975.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MKJ/

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, or

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☒ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

a. ☒ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached Form PTO/SB/08, reference is made to:

- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☒ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
 - f. ☒ A concise explanation of WO 2003/048363 is provided in the attached "Notice of Reasons for Rejection."
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.
6. ☐ Statement Under 37 CFR 1.704(d)

Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart application, and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Etsuko MIYAMOTO et al.

By /William R. Schmidt, II/
William R. Schmidt, II
Registration No. 58,327
Attorney for Applicants

Digitally signed by /William R. Schmidt, II/
DN: cn=/William R. Schmidt, II/, o, ou,
email=bschmidt@wenderoth.com,
c=US
Date: 2010.10.12 13:21:10 -04'00'

WRS/vah
Washington, D.C. 20005-1503
Telephone (202) 721-8200
Facsimile (202) 721-8250
October 12, 2010

Sheet 1 of 1		INFORMATION DISCLOSURE STATEMENT					
FORM PTO/SB/08 A&B (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) <i>(Use several sheets if necessary)</i> Date Submitted to PTO: October 12, 2010				ATTY DOCKET NO. 2006_0750A		SERIAL NO. 10/579,802	
				APPLICANT Etsuko MIYAMOTO et al.			
				FILING DATE May 18, 2006		GROUP 1636	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BA	03/048363	06/2003	WO			Abstract
	BB						
	BC						
	BD						
	BE						
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
	CA	Notice of Reason for Rejection from the Japanese Patent Office issued September 7, 2010 in corresponding Japanese Patent Application No. 2005-516432.					
	CB	E. Bengal et al., "Functional Antagonism between c-Jun and MyoD Proteins: A Direct Physical Association," <i>Cell</i> , Vol. 68, pp. 507-519, February 7, 1992.					
	CC	H. Yang-Yen et al., "Transcriptional Interference between c-Jun and the Glucocorticoid Receptor: Mutual Inhibitor of DNA Binding Due to Direct Protein-Protein Interaction," <i>Cell</i> , Vol. 62, pp. 1205-1215, September 21, 1990.					
	CD						
EXAMINER /Michele K. Joiike/				DATE CONSIDERED 10/13/2010			

*Examiner: ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MKJ/
 citation if not in conformance and not considered. Include copy of this form with next communication to applicant.